NCT05548231

A Study of LY3437943 in Chinese Participants With Obesity Or Overweight

A Multiple Dose Escalation Study in Chinese Participants With Overweight BMI or Obesity to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of LY3437943

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 32 (actual)
• Sponsor: Eli Lilly and Company · Industry
• Sex: All
• Age: 20 Years – 65 Years
• Healthy volunteers: Not accepted

Summary

The main purpose of this study is to learn about the safety and tolerability of LY3437943 when given to Chinese participants with overweight body mass index (BMI) or obesity. Blood tests will be performed to investigate how the body processes the study drug and how the study drug affects the body. Each enrolled participant will receive injections of LY3437943 or placebo given just under the skin. For each participant, the study will last about 20 weeks excluding screening period and may include up to 20 visits to the study center.

Conditions

• Overweight
• Obesity

Interventions

Type	Name	Description
DRUG	LY3437943	Administered SC
DRUG	Placebo	Administered SC

Timeline

• Start date: 2022-10-24
• Primary completion: 2023-07-27
• Completion: 2023-07-27
• First posted: 2022-09-21
• Last updated: 2023-08-14

Locations

2 sites across 1 country: China